Pyrocatechol Violet in Pharmaceutical Analysis Part II. A Spectrophotometric Method for the Determination of Paracetamol in Pure and in Pharmaceutical Dosage Forms [PDF]
Alaa S. Amin
openalex +1 more source
Digital Activity Markers in Chronic Inflammatory Demyelinating Polyneuropathy
ABSTRACT Objective To evaluate the utility of smartwatch and smartphone‐based activity metrics for assessing disease severity and quality of life in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Methods In the electronic monitoring of disease activity in patients with CIDP (EMDA‐CIDP) trial, we performed a prospective ...
Lars Masanneck+15 more
wiley +1 more source
ABSTRACT Objective We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti‐CD20 therapy on clinical and sub‐clinical outcomes in multiple sclerosis. Methods Clinical information was collected prospectively on Research Electronic Data Capture.
Nabil K. El Ayoubi+6 more
wiley +1 more source
Electrochemical study of anti-platelets tirofiban HCl in dosage form using nanomaterials modified sensors: developed and green assessed by eco-scale and complex-GAPI approach. [PDF]
Rizk M+3 more
europepmc +1 more source
Personalized medicine: An era of dosage form development
Upendra Nagaich
doaj +1 more source
New Oral Dosage Form for Elderly Patients: Preparation and Characterization of Silk Fibroin Gel.
Takehisa Hanawa+5 more
openalex +2 more sources
Simultaneous High-Performance Liquid Chromatographic Determination of Paracetamol, Phenylephrine HCl, and Chlorpheniramine Maleate in Pharmaceutical Dosage Forms [PDF]
Hamide Z. Şenyuva, Tugba Özden
openalex +1 more source
Safe to crush? A pilot study into solid dosage form modification in aged care
Nicole Mercovich, G. Kyle, M. Naunton
semanticscholar +1 more source
Efgartigimod Combined With Steroid Treatment for HAM/TSP: A Case Report
ABSTRACT HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive neurological disorder with limited treatment options. We report a 54‐year‐old female with decade‐long, progressive HAM/TSP, previously refractory to rituximab, who experienced worsening spastic paraparesis and neurogenic bladder dysfunction.
Jiahui Zeng+5 more
wiley +1 more source
Patient Acceptability and Preferences for Solid Oral Dosage Form Drug Product Attributes: A Scoping Review. [PDF]
Hauber B+7 more
europepmc +1 more source